BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine

Rebecca M. Jones¹, Panagiotis Kotsantis¹, Grant S. Stewart¹, Petra Groth², and Eva Petermann¹

Abstract

Replication inhibitors cause replication fork stalling and double-strand breaks (DSB) that result from processing of stalled forks. During recovery from replication blocks, the homologous recombination (HR) factor RAD51 mediates fork restart and DSB repair. HR defects therefore sensitize cells to replication inhibitors, with clear implications for cancer therapy. Gemcitabine is a potent replication inhibitor used to treat cancers with mutations in HR genes such as BRCA2. Here, we investigate why, paradoxically, mutations in HR genes protect cells from killing by gemcitabine. Using DNA replication and DNA damage assays in mammalian cells, we show that even short gemcitabine treatments cause persistent replication inhibition. BRCA2 and RAD51 are recruited to chromatin early after removal of the drug, actively inhibit replication fork progression, and promote the formation of MUS81- and XPF-dependent DSBs that remain unrepaired. Our data suggest that HR intermediates formed at gemcitabine-stalled forks are converted into DSBs and thus contribute to gemcitabine-induced cell death, which could have implications for the treatment response of HR-deficient tumors.

Mol Cancer Ther; 13(10); 2412–21. ©2014 AACR.

Introduction

Many cytotoxic anticancer treatments target proliferating cells by interfering with DNA replication, thus generating lethal DNA damage. Such treatments exploit the high proliferation rates of cancer cells, and can be further potentiated by cancer-specific defects in DNA repair (1). The mechanisms of action of two replication inhibitors, the ribonucleotide reductase (RNR) inhibitor hydroxyurea (HU) and the DNA polymerase inhibitor aphidicolin, have been studied in detail. Both cause slowing or stalling of replication forks, generating excessive amounts of ssDNA as DNA polymerases stall but the replicative helicase continues to unwind DNA. Replication inhibition activates the ATR-dependent S-phase checkpoint, which stabilizes stalled forks and downregulates new replication initiation (origin firing) to prevent further damage (2). After removal of the inhibitor, replication restarts and the checkpoint is inactivated. Depending on the length of treatment, restart occurs either by resumption of replication fork progression or through new origin firing (2, 3). After a few hours of replication block, structure-specific nucleases such as MUS81-EME1 begin to process the stalled forks into double-strand breaks (DSB; refs. 3, 4). Accumulation of these DSBs creates a requirement for the DSB repair pathways homologous recombination (HR) and nonhomologous end joining (NHEJ) for cellular resistance to replication inhibitors (5). HR depends on the recombinase RAD51 and mediator proteins such as XRCC3 and BRCA2, which promote the loading of RAD51 onto ssDNA. In addition to their roles in DSB repair, BRCA2 and RAD51 also prevent excessive MRE11-dependent resection of the daughter strands at stalled forks (6, 7) and RAD51 promotes restart of stalled forks after release from HU (3). All of these findings are of potential clinical importance as several types of cancer can have genetic defects in HR. This includes breast and pancreatic cancer, where familial and sporadic forms can display inactivating mutations or promoter methylation at BRCA1, BRCA2, PALB2, BRIP1, and other genes of the Fanconi Anemia pathway (8–11). Breast and pancreatic cancer are treated with the replication inhibitor gemcitabine (2’,2’-difluorodeoxycytidine). In the cells, gemcitabine is converted into its di- and triphosphates, which inactivate RNR and inhibit DNA polymerase after incorporation into nascent DNA (12). This strongly inhibits DNA synthesis and causes p53-independent apoptosis. The cytotoxic DNA lesions induced by gemcitabine and the DNA repair pathways that respond to them are poorly understood. Intriguingly, previous studies found that Chinese hamster cells mutated in BRCA2 or another HR mediator, XRC3, and the FANCC-mutated pancreatic cancer cell line PL11 were less sensitive to gemcitabine treatments than their HR-proficient counterparts (13–15).
Here, we investigate the molecular mechanism by which the HR factors BRCA2 and RAD51 promote gemcitabine-induced cell death. Our data suggest that even after short gemcitabine treatments, replication forks remain stalled and are converted into DSBs that persist in the cells. BRCA2 and RAD51 are recruited to chromatin, inhibit fork progression, and promote the formation of DSBs that are dependent on the structure-specific endonucleases MUS81 and XPF. Our data suggest that HR intermediates formed at stalled forks promote gemcitabine cytotoxicity, which could have implications for the treatment response of HR-deficient tumors.

Materials and Methods

Cell lines and reagents

Human cell lines were all obtained from ATCC more than 2 years ago and were therefore authenticated using 8-locus short tandem repeat profiling (LGC standards). Human U2OS osteosarcoma cells were last authenticated in April 2013. H1299 lung carcinoma cells were last authenticated in March 2011 and have not been cultured since. BxPC3 pancreatic adenocarcinoma cells, MCF7 breast cancer cells, and OVCAR3 human ovarian cancer cells were last authenticated in April 2014.

VC8 and VC8-B2 cells were obtained from Malgorzata Z. Zdziechicka (16, authentication not available). Cells were confirmed mycoplasma-free and grown in DMEM with 10% FCS in a humidified atmosphere containing 5% CO2. OVCAR3 cells were grown in DMEM with 10% FBS, 0.01 mg/mL insulin, and 1% nonessential amino acids (Sigma). Gemcitabine (Tocris Bioscience) was used at 2 or 5 μmol/L for 2 hours. DNA-PK inhibitor NU7441 (Tocris Bioscience) was used at 1 μmol/L. BLM inhibitor ML216 (Sigma-Aldrich) was used at 1.8 μmol/L as previously described (17).

DNA fiber analysis

Cells were labeled with 25 μmol/L CldU and 250 μmol/L IdU as indicated. For release from gemcitabine, cells were washed three times with warm PBS. Controls were labeled with CldU and IdU for 20 minutes each. DNA fiber spreads were prepared as described (3). Acid-treated fiber spreads were incubated with rat anti-BrdU (detects CldU, BU1/75; AbD Serotec) and mouse anti-BrdU (detects IdU, B44; Becton Dickinson) for 1 hour. Slides were fixed with 4% formaldehyde and permeabilized with 0.2% Triton X-100 for 5 minutes. For RAD51 foci, cells were pre-extracted with 0.2% Triton X-100 for 1 minute. For colocalization with replication foci, antibodies were fixed with 4% formaldehyde before DNA denaturation with HCl and immunostaining for thymidine analogues. Primary antibodies were rat monoclonal anti-BrdU (BU1/75, AbD Serotec; 1:400) to detect CldU, mouse monoclonal anti-BrdU (B44, Becton Dickinson, 1:50) to detect IdU, mouse monoclonal anti-phospho-Histone H2AX (Ser139; JBW301, Merck Millipore, 1:1000), rabbit polyclonal anti-RAD51 (H-92, Santa Cruz Biotechnology, 1:500), rabbit polyclonal anti-53BP1 (Bethyl, 1:3000), goat polyclonal anti-Lamin B (Santa Cruz Biotechnology, 1:400), and rabbit polyclonal anti-phospho-Histone H3 (Ser10; Merck Millipore, 1:500). Secondary antibodies were anti-Rat IgG AlexaFluor 555, anti-mouse IgG AlexaFluor 488, anti-rabbit IgG AlexaFluor 555, or AlexaFluor 647 and anti-goat IgG AlexaFluor 594 (Molecular Probes). DNA was counterstained with 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) and images acquired as above.

Cell survival assays

For clonogenic survival, defined numbers of cells were plated before treatment with gemcitabine (0.1–5 μmol/L) for 2 hours. Colonies of ≥50 cells were allowed to form in fresh medium, fixed and stained with 50% ethanol, 2% methylene blue for 10 minutes. Apoptosis was quantified by counting fragmented nuclei after DAPI staining and mitotic catastrophe was quantified by counting fragmented nuclei displaying Lamin B staining.

Flow cytometry

A total of 5 × 10⁵ cells per sample were treated as indicated, harvested and fixed with cold 70% ethanol before staining with propidium iodide (10 μg/mL). Cell-cycle profiles were gathered using the C6 Flow Cytometer system (Accuri) and analyzed with CFlow Plus.

Pulsed-field gel electrophoresis

A total of 2 × 10⁶ cells per sample were treated as indicated, harvested, and melted into 1.0% Agarose (Lonza) inserts. Inserts were digested in 0.5 mol/L EDTA-1% N-laurylsarcosyl-protease K (1 mg/mL) at room temperature for 48 hours and washed three times in Tris-EDTA (TE) buffer. Inserts were loaded onto a separation gel (1.0% chromosomal-grade agarose; Bio-Rad). Separation was performed using a CHEF DR III (Bio-Rad; 120-field angle, 240-second switch time, 4 V/cm, 14°C) for 20 hours. Images of ethidium bromide-stained gels were acquired using a Syngene G:BOX gel imaging system. DSBs (chromosome fragments >2 Mbp) were quantified by densitometry using ImageJ. Intensity of DNA entering the gel was normalized to total DNA and untreated control was subtracted to obtain final values.

siRNA treatment

siRNA against human RAD51 (14), MUS81 (siGENOME SMARTpool ID-016143), and XPF(ERCC4; OnTARGETplus
SMARTpool L-019946-00 were from Thermo Fisher. “All-stars negative control siRNA” (nonT) was from Qiagen. Cells were transfected with 50 nmol/L of each siRNA using Dharmafect 1 (Thermo Fisher) for 24, 48 (RAD51), or 72 hours (XPF and MUS81) before treatment with gemcitabine.

Western blotting
Primary antibodies were rabbit polyclonal anti-RAD51 (H-92, Santa Cruz Biotechnology, 1:500), mouse monoclonal anti-MUS81 (MTA30 2G10/3, Santa Cruz Biotechnology, 1:500), mouse monoclonal anti-XPF (219, Fisher Scientific, 1:200), mouse monoclonal anti-XPF (Cell Signaling Technology, 1:1,000), and mouse monoclonal anti-PARP1 (F-2, Santa Cruz Biotechnology, 1:500). For Fisher, 1:5,000), rabbit polyclonal anti–

Statistical analysis
The mean and 1 × SEM of independent repeats are shown. Statistical significance was determined using the Student t test (*, P < 0.05; **, P < 0.01; *** P < 0.001).

Results
We used BRCA2-mutated VC8 and BRCA2-complemented VC8-B2 Chinese hamster fibroblasts (p53 mutated), an isogenic model for BRCA2 function that has successfully been used to study the role of BRCA2 in chemotherapy response (18). We tested short gemcitabine treatments in the micromolar range, similar to clinically relevant concentrations (19, 20). Although VC8 cells were hypersensitive to cisplatin as expected (Supplementary Fig. S1A), they were less sensitive than VC8-B2 cells to higher concentrations of gemcitabine (Fig. 1A). Similar results were obtained after siRNA-depleting RAD51 in human U2OS osteosarcoma and BxPC3 pancreatic cancer cell lines (both p53 wild-type), suggesting that this was not due to secondary mutations acquired in VC8 cells, but to loss of RAD51 function (Fig. 1B and C and Supplementary Fig. S1B).

We initially used 2 µmol/L gemcitabine, which has been shown to inhibit fork progression and allowed about 50% survival in our cell lines, and measured replication restart using DNA fiber analyses (Fig. 1D). Even at this low concentration, most forks remained stalled and did not resume progression for at least 24 hours after release from 2 hour gemcitabine (Fig. 1D). Levels of fork stalling were comparable between BRCA2-proficient and -deficient cells and similar results were obtained using RAD51-depleted U2OS cells (Fig. 1E and F). Levels of phospho-S139-H2AX ($\gamma$H2AX), a marker of stalled forks (3), increased after gemcitabine release and remained high for at least 72 hours, suggesting that stalled forks persisted for several days (Fig. 1G and H). The induction of $\gamma$H2AX was comparable in BRCA2-proficient and -deficient as well as control- and RAD51-depleted cells (Fig. 1G and H). However, BRCA2-deficient cells displayed lower $\gamma$H2AX staining after 72 hours release, suggesting a quicker recovery from gemcitabine-induced DNA damage (Fig. 1G). Overall these data did not suggest that promotion of fork restart by BRCA2 or RAD51 plays a role in response to cytotoxic gemcitabine treatments.

Despite persistent fork stalling, cells resumed replication between 6-hour and 24-hour release, firing new origins and resuming slow progression through S phase (Fig. 2A and B). Nevertheless, markers of S-phase checkpoint signaling remained active during replication restart (Supplementary Fig. S2). Cell-cycle progression was accompanied by apoptosis and mitotic catastrophe (MC), which peaked after 2 to 3 days release (Fig. 2B and C). The appearance of MC suggests that some cell death did result from aberrant mitotic entry in presence of unrepaired DNA damage (21). VC8 cells displayed lower induction of MC and apoptosis after 5 µmol/L gemcitabine (Fig. 2D), which was not due to VC8 cells being prevented from cycling and mitotic entry. Instead, VC8 cells displayed higher percentages of cells positive for phospho-histone H3 (Fig. 2E) and faster progression into the next G1 phase 1 day after release compared with VC8-B2 cells (Fig. 2F). Initial accumulation in S phase was also not lower in BRCA2-deficient cells (Fig. 2F), confirming that reduced gemcitabine sensitivity was not due to fewer cells entering S phase. Interestingly, VC8 cells displayed fewer $\gamma$H2AX-positive cells and a lower percentage of S-phase cells at 3 days after release, suggesting a quicker recovery from gemcitabine in absence of BRCA2 (Fig. 1G and 2F).

We decided to further investigate the role of BRCA2 and RAD51 at gemcitabine-stalled replication forks. In addition to promoting fork restart, RAD51 and BRCA2 also prevent shortening of daughter strands at stalled forks (6, 7), and RAD51 inhibits fork progression during cisplatin and camptothecin treatments (22, 23). To investigate if either of these processes occurs after release from gemcitabine, we compared the length of DNA replicated during 2-hour gemcitabine treatment and after 4-hour release from 5 µmol/L gemcitabine in VC8 and VC8-B2 cells (Fig. 3A). Tracks replicated during the 2-hour gemcitabine treatment were longer in presence of BRCA2, as has been described before (6). However, after release from gemcitabine, replicated tracks in BRCA2-proficient cells remained the same length, whereas tracks in BRCA2-deficient cells further increased in length, suggesting that some forks were still progressing (Fig. 3B, C, and F). Similar results were obtained using RAD51-depleted U2OS cells (Fig. 3D, E, and G). Our data suggest that after release from gemcitabine, BRCA2 and RAD51 are recruited to forks where RAD51 promotes transactions that inhibit further fork progression. In HR-proficient cells, RAD51 foci indeed accumulated and persisted for 72 hours after release (Fig. 3H and I), suggesting that HR was initiated but not completed during that time.

Next, we tested whether gemcitabine-stalled forks were processed into DSBs. We first measured accumulation of
nuclear 53BP1 foci, which mark sites of DSBs (24). High numbers of 53BP1 foci that colocalized with replication foci accumulated after 2- and 16-hour release in U2OS and VC8-B2 cells, respectively (Fig. 4A and B). Compared with γH2AX foci (Fig. 1G and H), 53BP1 foci formation was delayed and only around half of γH2AX-positive cells also contained 53BP1 foci. This supports the idea that γH2AX marks all stalled replication forks as well as DSBs, whereas 53BP1 only accumulates at the subset of forks that have been processed into DSBs. Pulsed-field gel electrophoresis (PFGE) of genomic DNA confirmed that the increase in 53BP1 foci correlated with an increase in DSB levels (Fig. 4C and Supplementary Fig. S3A). As with RAD51 foci, DSB levels remained high for 2 to 3 days after release, suggesting that little DSB repair was occurring.

As DSBs are highly toxic DNA lesions and likely to contribute to gemcitabine toxicity, we next analyzed
whether gemcitabine-induced DSB formation depended on BRCA2 and RAD51. Indeed, PFGE showed that although VC8 cells displayed higher background levels of unrepaired DSBs, the additional increase in DSBs after gemcitabine was higher in the presence of BRCA2 (Fig. 4D and E and Supplementary Fig. S3B). Similarly, RAD51-depleted U2OS cells accumulated fewer 53BP1 foci than control cells after release from gemcitabine (Fig. 4F–H).

Comparable results were obtained in RAD51-depleted human cancer cell lines derived from pancreatic (BxPC3, p53 wild-type), breast (MCF7, p53 wild-type), and ovarian cancer (OVCAR3, p53 mutated; Supplementary Figs. S4–S6). HR-deficient cells thus accumulate fewer DSBs after gemcitabine treatment.

In addition to HR, NHEJ acts as an alternative and competing repair pathway for DSBs. Although NHEJ may not be able to faithfully repair one-ended DSBs at collapsed replication forks, it can promote resistance to replication inhibitors such as HU, suggesting that some replication-dependent breaks are substrates for NHEJ (5). We considered that reduced gemcitabine sensitivity in HR-deficient cells might result from DSBs being more efficiently repaired by NHEJ in absence of HR. We inhibited NHEJ using DNA-PK inhibitor NU7441 to test whether this could sensitize HR-deficient cells to gemcitabine. NU7441 alone increased the background levels of unrepaired DSBs (Supplementary Fig. S3B). However, cotreatment with NU7441 did not increase gemcitabine toxicity (Fig. 5A) or gemcitabine-induced DSB levels in BRCA2-deficient cells (Fig. 5B and Supplementary Fig. S3B). In contrast, BRCA2-proficient cells treated with NU7441 were more sensitive to gemcitabine and accumulated more DSBs early after release from gemcitabine (Fig. 5A and B), suggesting that some BRCA2-dependent DSBs are repaired by NHEJ.

To further support a role for HR in gemcitabine-induced DSB formation and cell death, we used a small-molecule inhibitor of the BLM helicase, ML216 (17). BLM counteracts RAD51 function in the initiation of HR by resolving D-loop structures (25). If RAD51-mediated HR is responsible for gemcitabine-induced DSBs and cell death, then BLM inhibition should exacerbate both DSB formation and cell death. Indeed, we observed a small but reproducible increase in DSBs and cell death in cells treated with BLM inhibitor (Fig. 5C and D).
forks into DSBs, focusing on the MUS81-EME1 and XPF-ERCC1 structure–specific endonucleases. In vitro, only MUS81-EME1 cleaves stalled replication fork structures, but in vivo XPF-ERCC1 and MUS81-EME1 can act in parallel pathways to process joint molecule recombination intermediates such as Holliday junctions (26, 27). Cells were transfected with XPF or MUS81 siRNA for 72 hours, treated with 5 μmol/L gemcitabine for 2 hours, and released for up to 72 hours. Proteins remained depleted for at least 2 days after treatment (Fig. 6A–C). Depletion of MUS81 or XPF could prevent gemcitabine-induced DSB formation, with codepletion of both proteins being more effective (Fig. 6D and E). DSBs in gemcitabine-treated cells thus depend on BRCA2 and RAD51, and therefore likely on RAD51 loading and filament formation for the initiation of HR, and on endonucleases that cleave HR intermediates. These data suggest that these DSBs arise not only simply through endonucleolytic cleavage of stalled
replication forks, but also through processing of recombination intermediates.

Discussion

We report that after release from gemcitabine treatment, BRCA2 and RAD51 inhibit replication fork progression, promote MUS81/XPF-dependent DSB formation, and exacerbate cell death. This supports the idea that initiation of HR is required for DNA damage formation at gemcitabine-stalled replication forks. HR, normally a pathway that prevents accumulation of DNA damage, can thus promote the formation of DNA damage after gemcitabine treatment.

We speculate that in response to gemcitabine, BRCA2-assisted loading of RAD51 onto replication forks promotes the generation of HR intermediates, which inhibit further fork progression. This is likely the same mechanism as the RAD51-mediated fork slowing previously observed in cisplatin- or camptothecin-treated cells (22, 23), although the cellular consequences of this phenomenon have not been described. We speculate that these HR intermediates, likely D-loops and Holliday junctions, present substrates for endonucleolytic processing.

Figure 4. Gemcitabine causes DSBs that depend on BRCA2 and RAD51. A, 53BP1 foci (far-red) and colocalization with replication foci (CldU, red and IdU, green) in VC8-B2 cells 6 hours after release from 2 μmol/L gemcitabine. Bars, 10 μm. B, percentages of cells displaying more than 10 53BP1 foci after release from gemcitabine (asterisks compared with Con). C, PFGE showing DSB induction after release from 2 μmol/L gemcitabine in U2OS and VC8-B2 cells (see Supplementary Fig. S3A for quantification). D, PFGE of DSB induction in VC8-B2 and VC8 cells after release from 5 μmol/L gemcitabine (cropped lanes are from one gel, see Supplementary Fig. S3B), E, percentages of DNA released from plugs in DSB in VC8-B2 and VC8 cells. F, outline of experimental design for 53BP1 foci quantification. Twenty-four hours after transfection with RAD51 or nonT siRNA, U2OS cells were treated with 5 μmol/L gemcitabine for 2 hours, released for the times indicated, fixed and stained for 53BP1. G, representative images of 53BP1 foci in U2OS cells ± RAD51 siRNA released from 5 μmol/L gemcitabine. Bar, 10 μm. H, percentages of U2OS cells ± RAD51 siRNA displaying more than 10 53BP1 foci after release from 5 μmol/L gemcitabine. Error bars, SEM; †, P < 0.05; ‡, P < 0.01; ‡‡, P < 0.001, Student t test.
by MUS81 and XPF to generate DSBs (Fig. 6F). Gemicitabine-induced DSBs are not efficiently repaired, which could explain why HR does not protect from cell death. We speculate that the processes described here also occur at forks that have been stalled by other types of replication inhibitors, but this may not be obvious if the inhibitor also induces DSBs by other mechanisms and does not prevent HR-mediated DSB repair. Our data suggest that for transient treatments, DNA damage response factors that promote rearrangements and nuclease processing of stalled forks can be expected to cause sensitivity to gemcitabine (Fanconi Anemia proteins, BRCA2, XRCC3, RAD51), whereas factors involved in later steps of DSB repair should promote survival or have little effect (DNA Ligase IV, RAD54).

Our data also suggest that the very persistent effects of even short exposures to gemcitabine are important for its cytotoxic action. Gemicitabine inactivates RNR irreversibly and gemcitabine nucleotides accumulate in cells after treatment (12), which likely underlies the prolonged replication inhibition observed. After release from gemcitabine, stalled replication forks and DNA damage signaling therefore persist, but cannot prevent the eventual resumption of cell-cycle progression. A similar phenomenon has been observed during prolonged HU treatments and could be common to all situations of prolonged replication fork stalling (4, 28). This cell-cycle progression in presence of unresolved DNA lesions contributes to cell death by mitotic catastrophe and likely also to DSB formation and apoptosis, as mitotic CDK1 activity has been suggested to promote MUS81-dependent DSB formation at perturbed forks (29).

These peculiarities of transient gemcitabine treatments could explain why reports on the impact of HR status on gemcitabine sensitivity are still conflicting. Previous studies have variously used continuous or transient treatments. For example, RAD51 depletion sensitizes cells to continuous treatment with low doses of gemcitabine (30, 31), but both RAD51 depletion and mutations in BRCA2 decrease sensitivity when combined with transient treatments at higher doses, which seem more relevant for clinical applications (15 and this study). Indeed, a recent study showed that ATR and CHK1 inhibitors could sensitize ovarian cancer cells to transient but not to continuous gemcitabine treatments (32). As ATR and CHK1 protect stalled forks from DSB formation, this suggests that the danger of DSB is higher after release from gemcitabine than during continuous treatment, possibly due to increased cell-cycle progression. In agreement with this, our preliminary data suggest that more DSBs can be detected after release from transient gemcitabine treatment compared with continuous treatment for the same time (Supplementary Fig. S7). On the other hand, mutations in the HR genes XRCC3 and FANCC can promote resistance even to continuous gemcitabine treatments (13, 14). This suggests that more research into the time course of gemcitabine action is needed, especially as this information could be crucial for optimal scheduling in combination treatments such as gemcitabine/carboplatin.

Figure 5. Roles of NHEJ and BLM helicase in the response to gemcitabine. A, clonogenic survival of VC8-B2 and VC8 cells treated with gemcitabine and 1 μmol/L NU7441 for 2 hours and released into fresh medium containing 1 μmol/L NU7441, compared with survival without NU7441 (Fig. 1A). B, percentages of DNA released from plugs in DSB in VC8-B2 and VC8 cells released from treatment with 5 μmol/L gemcitabine in presence or absence of 1 μmol/L NU7441 (see Supplementary Fig. S3B for gel). Error bars, SD. C, percentages of U2OS cells ± BLM inhibitor displaying more than 10 53BP1 foci after release from 5 μmol/L gemcitabine. Cells were preincubated with 1.8 μmol/L BLM inhibitor for 1 hour before gemcitabine treatment and released in fresh medium containing BLM inhibitor. D, clonogenic survival of U2OS cells ± BLM inhibitor treated with gemcitabine for 2 hours as in C. Error bars, SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001, Student t test.
There are three published case studies of patients with pancreatic cancer carrying BRCA2 or PALB2 mutations that did not respond or responded poorly to gemcitabine, but responded well to a subsequent treatment with the crosslinking agents cisplatin or mitomycin C (33–35). Although we do not consider these data evidence that HR-deficient pancreatic cancers are more resistant to gemcitabine than other pancreatic cancers, they do show that cancers that have proven resistant to one DNA-damaging agent (gemcitabine) can be hypersensitive to a different DNA-damaging agent (e.g., carboplatin). This also suggests that in the case of gemcitabine/platinum combination therapies, the hypersensitivity of HR-deficient tumors to platinum compounds could compensate for any gemcitabine resistance in these tumors.

Taken together, our data have potential implications for the scheduling of gemcitabine combination treatments in general and pose the question as to whether HR-deficient tumors would respond well to single-agent gemcitabine treatments.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: R.M. Jones, P. Kotsantis, E. Petermann
Development of methodology: R.M. Jones, P. Kotsantis, E. Petermann
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R.M. Jones, P. Kotsantis, G.S. Stewart, P. Groth
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R.M. Jones, P. Kotsantis, P. Groth, E. Petermann
Writing, review, and/or revision of the manuscript: R.M. Jones, P. Kotsantis, G.S. Stewart, E. Petermann
Study supervision: E. Petermann
References


BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine

Rebecca M. Jones, Panagiotis Kotsantis, Grant S. Stewart, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-13-0862</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://mct.aacrjournals.org/content/suppl/2014/07/23/1535-7163.MCT-13-0862.DC1">http://mct.aacrjournals.org/content/suppl/2014/07/23/1535-7163.MCT-13-0862.DC1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 35 articles, 17 of which you can access for free at: <a href="http://mct.aacrjournals.org/content/13/10/2412.full#ref-list-1">http://mct.aacrjournals.org/content/13/10/2412.full#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 4 HighWire-hosted articles. Access the articles at: <a href="http://mct.aacrjournals.org/content/13/10/2412.full#related-urls">http://mct.aacrjournals.org/content/13/10/2412.full#related-urls</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>